Marc Ladanyi

TL;DR: It is demonstrated that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival, and a large majority of SCNAs identified in individual cancer types are present in several cancer types.

TL;DR: The genomic features of endometrial carcinomas permit a reclassification that may affect post-surgical adjuvant treatment for women with aggressive tumours, and these features are classified into four categories: POLE ultramutated, microsatellite instability hypermutated, copy- number low, and copy-number high.

TL;DR: In this paper, the authors identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions.

TL;DR: Although in vitro data supported the use of either ERBB3 or ERBB2 inhibition, clinical results were consistent with more profound antitumor activity and downstream signaling inhibition with anti-ERBB3 versus anti-ERGBB2 therapy in an NRG1-rearranged patient-derived xenograft model.

TL;DR: Using isogenic and patient-derived models, KRAS mutation results in constitutive activation of RAS/ERK signaling and resistance to MET inhibition, and dual inhibition of MET or EGFR/ERBB2 and MEK reduced growth of cell line and xenograft models.